TRINETRA › Sectors › Healthcare
Supriya Lifescience Limited (SUPRIYA) — share price, P/E and fundamentals
Supriya Lifescience Limited (NSE: SUPRIYA) closed at ₹860.00 on 30 Oct 2026, +16.4% over one year, against a 52-week range of ₹545.50 – ₹1,085.00.
In the quarter ended 30 Jun 2026 (standalone, filed 13 Aug 2026) it reported revenue of ₹190 cr and net profit of ₹24 cr, a 12.7% net margin; revenue grew 30.8% and profit fell 14.0% year on year.
On four consecutive filed quarters its trailing P/E is 34.9; since 27 May 2025 its own P/E has ranged from 24.0 to 40.6 (median 31.3), and today's reading is higher than 84% of those 353 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 8.0%, ROCE 13.3%, debt-to-equity 0.00, Piotroski F-score 5 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 49% of 63 sector peers; PBT margin higher than 64% of 63 sector peers; ROE higher than 16% of 63 sector peers.
Key figures
| Last close | ₹860.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -10.6% / +33.8% / +16.4% |
| 52-week low – high | ₹545.50 – ₹1,085.00 |
| Market capitalisation | ₹6,922 cr |
| Trailing P/E | 34.9 |
| Price / book | 5.78 |
| EV / EBITDA | 22.9 |
| Earnings yield | 2.9% |
| TTM EPS | ₹24.65 |
| TTM net profit | ₹198 cr |
| Quarter revenue | ₹190 cr |
| Quarter net profit | ₹24 cr |
| Net margin | 12.7% |
| Revenue growth (YoY) | +30.8% |
| Profit growth (YoY) | -14.0% |
| Return on equity | 8.0% |
| ROCE | 13.3% |
| Debt / equity | 0.00 |
| Current ratio | 4.40 |
| Free cash flow | ₹34 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹17.2 cr |
Against Healthcare peers
| Metric | SUPRIYA | Peer median | Percentile |
|---|---|---|---|
| Net margin | 12.67 | 12.89 | 49 |
| PBT margin | 21.50 | 17.57 | 64 |
| ROE | 8.03 | 13.87 | 16 |
| ROCE | 13.32 | 17.26 | 30 |
| Debt / equity | 0.00 | 0.11 | 12 |
| Cash conversion | 0.89 | 1.25 | 25 |
| Trailing P/E | 34.89 | 43.26 | 27 |
| P/B | 5.78 | 6.02 | 48 |
Questions
What is the P/E ratio of Supriya Lifescience Limited?
Supriya Lifescience Limited's trailing P/E is 34.9, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 27 May 2025 its P/E has ranged 24.0–40.6.
What were Supriya Lifescience Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Supriya Lifescience Limited reported revenue of ₹190 cr and net profit of ₹24 cr (standalone), filed with the exchange on 13 Aug 2026.
What is Supriya Lifescience Limited's ROE?
Return on equity is 8.0% based on the balance sheet dated 31 Mar 2026.
Does Supriya Lifescience Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.
What is SUPRIYA's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SUPRIYA traded between ₹545.50 and ₹1,085.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: standalone SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.